Matinas BioPharma Holdings Inc MTNB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.81
- Day Range
- $0.75–0.80
- 52-Week Range
- $0.75–14.63
- Bid/Ask
- $0.70 / $0.80
- Shares Outstanding
- 1.11M
- Market Cap
- $890,711.05
- Volume/Avg
- 37,089 / 91,909
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
Valuation
Metric | MTNB |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.19 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | MTNB |
|---|---|
Quick Ratio | 1.62 |
Current Ratio | 1.78 |
Interest Coverage | — |
Quick Ratio
MTNB
Profitability
Metric | MTNB |
|---|---|
Return on Assets (Normalized) | −107.09% |
Return on Equity (Normalized) | −171.93% |
Return on Invested Capital (Normalized) | −136.81% |
Return on Assets
MTNB
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|&tbTB&> | LOCK|qh%! | $132B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|##W!zb | LOCK|bVj& | $96B | |||
| Moderna Inc MRNA | LOCK|xM@%X<& | LOCK|B%V | $81B | |||
| argenx SE ADR ARGX | LOCK|<@c$rZY | LOCK|T?z | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|&Cq&R? | LOCK|Cpj | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|BG&RbB$ | LOCK|&qCSR | $30B | |||
| Incyte Corp INCY | LOCK|r>?K#> | LOCK|L% | $24B | |||
| BioNTech SE ADR BNTX | LOCK|hqzwRJ | LOCK|M>b | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|>z^S@% | LOCK|lK!cT | $20B | |||
| BridgeBio Pharma Inc BBIO | LOCK|ZZS<?c | LOCK|c& | $15B |